Immunovia Provides Complementary Details on the IMMray[™] PanCan-d Verification Study
LUND, SWEDEN – Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced further details regarding the outcomes of the Verification Study. As previously communicated, the Verification study is the step in the development process where samples are run on the final commercial product with the locked biomarker signature that was derived from the previous Commercial Test Model Study. The Verification Study included samples collected from six sites in Europe and three sites in the US, which mirrors the